In one paragraphArticle in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
15 authors.
Tadashi YamamuroDivision of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center and Harvard Medical School, and Howard Hughes Medical Institute, Boston, MA, USA.ORCID 0000-0002-0610-5204 Daisuke KatohDivision of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center and Harvard Medical School, and Howard Hughes Medical Institute, Boston, MA, USA.ORCID 0000-0001-6576-0463 Guilherme Martins SilvaCenter for Drug Discovery and Translational Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-7571-9090 Hiroshi NishidaDivision of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center and Harvard Medical School, and Howard Hughes Medical Institute, Boston, MA, USA.ORCID 0000-0003-0284-5771 Satoshi OikawaDivision of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center and Harvard Medical School, and Howard Hughes Medical Institute, Boston, MA, USA.ORCID 0000-0002-7696-8128 Yusuke HiguchiDivision of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center and Harvard Medical School, and Howard Hughes Medical Institute, Boston, MA, USA.ORCID 0000-0001-6885-2945 Dandan WangDivision of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center and Harvard Medical School, and Howard Hughes Medical Institute, Boston, MA, USA.ORCID 0009-0006-2788-7475 Masanori FujimotoDivision of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center and Harvard Medical School, and Howard Hughes Medical Institute, Boston, MA, USA.ORCID 0000-0003-1458-8207 Naofumi YoshidaDivision of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center and Harvard Medical School, and Howard Hughes Medical Institute, Boston, MA, USA.ORCID 0000-0003-3949-0089 Mark LiDivision of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center and Harvard Medical School, and Howard Hughes Medical Institute, Boston, MA, USA.ORCID 0009-0000-9038-6725 Jihoon ShinDivision of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center and Harvard Medical School, and Howard Hughes Medical Institute, Boston, MA, USA.ORCID 0000-0003-1294-0238 Zezhou ZhaoDivision of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center and Harvard Medical School, and Howard Hughes Medical Institute, Boston, MA, USA.ORCID 0000-0003-4792-6073 Jin-Seon YookDivision of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center and Harvard Medical School, and Howard Hughes Medical Institute, Boston, MA, USA.ORCID 0000-0002-9294-6770 Lijun SunCenter for Drug Discovery and Translational Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-1579-2253 Shingo KajimuraDivision of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center and Harvard Medical School, and Howard Hughes Medical Institute, Boston, MA, USA.ORCID 0000-0003-0672-5910 Funding
Molecular mechanisms of UCP1-independent pathways in metabolic healthR01DK097441 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Shingo Kajimura · 2012 to 2026
$5.9MMitochondrial Metabolite Compartmentalization in Health and DiseaseDP1DK126160 · NIDDK · BETH ISRAEL DEACONESS MEDICAL CENTER · PI KAJIMURA, SHINGO · 2020 to 2025
$4.4MMitochondrial BCAA transporter in physiology and diseaseR01DK125283 · NIDDK · BETH ISRAEL DEACONESS MEDICAL CENTER · PI KAJIMURA, SHINGO · 2021 to 2025
$1.8MNIDDK NIH HHS DP1 DK126160NIDDK NIH HHS R01 DK097441NIDDK NIH HHS R01 DK125283
6 · The paper itselfAbstract
Mitochondria provide a variety of metabolites, in addition to ATP, to meet cell-specific needs. One such metabolite is phosphoenolpyruvate (PEP), which contains a higher-energy phosphate bond than ATP and has diverse biological functions. However, how mitochondria-generated PEP is delivered to the cytosol and fulfills cell-specific requirements remains elusive. Here, we show that SLC25A35 regulates mitochondrial PEP efflux and glyceroneogenesis in lipogenic cells that utilize the pyruvate-to-PEP bypass. Reconstitution and structural studies demonstrated PEP transport by SLC25A35 in a pH gradient-dependent manner. Loss of SLC25A35 in adipocytes impaired the conversion of mitochondrial PEP into glycerol-3-phosphate, thereby reducing glycerolipid synthesis. Significantly, hepatic inhibition of SLC25A35 in obese mice alleviated steatosis and improved systemic glucose homeostasis. Together, these results suggest that mitochondria facilitate glycerolipid synthesis by providing PEP via SLC25A35, offering lipogenic mitochondria as a target to limit glycerolipid synthesis, a pivotal step in the pathogenesis of hepatic steatosis and Type 2 diabetes.
Indexed as
BioenergeticsDiabetesGlyceroneogenesisHepatic SteatosisMitochondriaObesity
Identifiers
PMID41446167
PMCPMC12724411
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390